STOCK TITAN

Savara (SVRA) Stock News, Mar-Aug 2023

SVRA NASDAQ

Savara Inc. develops therapies for rare respiratory diseases, with a lead program in molgramostim inhalation solution, conditionally named MOLBREEVI, for autoimmune pulmonary alveolar proteinosis. Molgramostim is a recombinant human GM-CSF delivered through an investigational eFlow Nebulizer System developed for inhalation of the large-molecule therapy.

Recurring company developments include clinical data from the IMPALA-2 program, regulatory submissions and agency-review updates in the U.S., Europe and the U.K., financial results, financing arrangements, equity inducement grants and investor conference participation. Savara's updates also note that MOLBREEVI is not approved in any indication.

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.04%
Tags
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.95%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.92%
Tags
News
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.13%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.34%
Tags
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.02%
Tags
conferences
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.50%
Tags
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.45%
Tags
none
-
Rhea-AI Summary

Savara Inc. (NASDAQ: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the grant of inducement awards to two new employees on March 29, 2023. The awards include options to purchase a total of 30,000 shares at an exercise price of $2.03, equivalent to the stock's closing price on the grant date. The options will vest at a rate of 1/16th quarterly over ten years, contingent upon continued employment. Savara's lead program, molgramostim nebulizer solution, is in Phase 3 development for autoimmune pulmonary alveolar proteinosis.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.15%
Tags
none
Rhea-AI Summary

Savara Inc. (Nasdaq: SVRA) announced that its pivotal Phase 3 IMPALA-2 trial evaluating molgramostim for autoimmune Pulmonary Alveolar Proteinosis is on track, with top-line data expected by the end of Q2 2024. Following a positive review from the Independent Data Monitoring Committee, the trial proceeds unmodified. The company also reported a net loss of $10.3 million for Q4 2022, maintaining a stable loss per share of $(0.07), and ended 2022 with $125.9 million in cash. Savara aims to launch a global aPAP market development campaign in 2H23 and believes it is sufficiently capitalized through 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.41%
Tags

FAQ

What is the current stock price of Savara (SVRA)?

Savara (SVRA) last closed at $4.64.

What is the market cap of Savara (SVRA)?

The market cap of Savara (SVRA) is approximately $1.0B.